drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Bispecific T-cell–engaging monoclonal antibody (IgG, 2:1 format) targeting CD20 on B cells and CD3 on T cells to activate T cells and mediate cytotoxic killing of malignant B cells.
nci_thesaurus_concept_id
C148486
nci_thesaurus_preferred_term
Glofitamab
nci_thesaurus_definition
A bispecific monoclonal antibody, with potential antineoplastic activity. Glofitamab contains two antigen-recognition sites: one for human CD3, a T cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, glofitamab binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells.
drug_mesh_term
glofitamab
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
A 2:1 CD20×CD3 bispecific monoclonal antibody that simultaneously binds CD20 on B cells and CD3 on T cells, forming an immune synapse to activate TCR/CD3 signaling and redirect T-cell cytotoxicity (perforin/granzyme) to kill and deplete malignant CD20+ B cells.
drug_name
Glofitamab
nct_id_drug_ref
NCT06481826